10 Best Future Stocks to Buy for the Next 5 Years

In this article, we will discuss the 10 Best Future Stocks to Buy for the Next 5 Years.

On March 25, Scott Chronert of Citi joined ‘Closing Bell’ on CNBC to discuss whether it is time to enter the market and if recent presidential actions have changed the market dynamic. In the short term, Chronert noted that market positioning had been skewed negatively over the past three weeks as the conflict in Iran unfolded.

He suggested that any perceived alleviation of risk regarding the duration of that conflict would lead to a more positive tape, which accounts for the market’s behavior over the last day or two. On the flip side, Chronert explained that the intermediate-term outlook remains different and more complex. He emphasized the need to monitor specific inputs, including how oil prices trade over the intermediate term and the resulting implications for interest rates and currency. Furthermore, he pointed to the importance of upcoming corporate fundamentals as the market enters the Q1 reporting period.

While he acknowledged that the short-term outlook appears positive, he cautioned that there is still wood to chop for the intermediate term. Furthermore, Chronert explained that the earlier thesis for the year, which involved a broadening of the market into small-cap, mid-cap, and other non-tech sectors, was predicated on Goldilocks economics, a soft landing, and an easier Federal Reserve. However, as oil prices remain longer and higher, those economic assumptions become more problematic for the market’s broader sectors.

Our Methodology

We sifted through financial media reports to find stocks with multi-year growth opportunities. We then used screeners to identify stocks that are expected to grow their earnings by at least 25% over the next 5 years, and limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.

Note: All data was sourced on April 3. 

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

10 Best Future Stocks to Buy for the Next 5 Years

10. STMicroelectronics (NYSE:STM)

STMicroelectronics (NYSE:STM) is one of the best future stocks to buy for the next 5 years. On March 17, STMicroelectronics announced the expansion of its 800 VDC power conversion portfolio through the introduction of new 12V and 6V architectures developed in collaboration with Nvidia. These solutions complement the company’s existing 800 VDC to 50V stage and are designed to support the 800 VDC reference design.

This expansion aims to provide a complete portfolio for power distribution within gigawatt-scale AI datacenter infrastructure, using STMicroelectronics’ (NYSE:STM) power, analog, and mixed-signal technologies with custom chip and package-level designs. The new architectures address the industry’s shift toward diverse server configurations and power delivery topologies required for high-density AI infrastructures.

While the 12V converter enables high-efficiency distribution from rack-level power shelves to advanced AI accelerators, the 6V path allows OEMs to move the bus closer to the GPU. These developments help reduce copper usage, minimize resistive losses, and improve transient performance. The 50V, 12V, and 6V intermediate DC buses are expected to coexist depending on specific rack density, GPU configuration, and cooling strategies. Technically, the direct 800 VDC to 12V conversion eliminates traditional intermediate stages to reduce system-level losses and simplify integration for future GPU generations.

STMicroelectronics (NYSE:STM) is a technology company that specializes in semiconductor products and operates through four segments: AM&S (Analog products, MEMS & Sensors Group), P&D (Power and Discrete products), EMP (Embedded Processing), and D&RF (RF Products).

9. Bloom Energy Corporation (NYSE:BE)

Bloom Energy Corporation (NYSE:BE) is one of the best future stocks to buy for the next 5 years. On March 26, Bloom Energy announced the appointment of Simon Edwards as Chief Financial Officer, effective April 13. Edwards brings ~20 years of experience in scaling technology companies, with a background that combines operational rigor and expertise in digital infrastructure.

This hire aligns with the company’s focus on addressing power availability constraints currently impacting the growth of the AI industry. Edwards joins Bloom Energy from Groq, where he served as CEO and CFO, overseeing global financial operations and infrastructure expansion during a period of rapid growth. His career includes CFO roles at SaaS leaders Conga and ServiceMax, as well as senior leadership positions at GE, including CFO of GE Digital.

His professional history provides a foundation in manufacturing, digital transformation, and data-driven operational excellence across various tech sectors. According to Founder and CEO KR Sridhar, Edwards’ engineering background and experience with AI infrastructure will strengthen the management team as Bloom Energy Corporation (NYSE:BE) builds power platforms for the digital economy.

Bloom Energy Corporation (NYSE:BE) is an electrical equipment & parts company that specializes in solid oxide fuel cell systems for on-site power generation. The company also provides the Bloom Energy Server to convert fuel into electricity.

8. TKO Group Holdings Inc. (NYSE:TKO)

TKO Group Holdings Inc. (NYSE:TKO) is one of the best future stocks to buy for the next 5 years. On March 10, TKO Group announced a $1 billion share repurchase initiative, consisting of an $800 million accelerated share repurchase/ASR agreement and a 10b5-1 trading plan for up to $200 million. These actions are part of the company’s previously established $2 billion share repurchase authorization.

Under the terms of the ASR Agreement, TKO Group was to pay $800 million to Morgan Stanley & Co. LLC on March 11. The company expects an initial delivery of 3,136,179 shares of Class A common stock, with the final number of shares determined by the volume-weighted average price during the agreement’s term. These transactions are scheduled to conclude in June this year, nearly exhausting the total $2 billion authorization.

The secondary component of the announcement involves a 10b5-1 trading plan, which is set to commence once the ASR Agreement transactions are finalized. This plan allows for the additional repurchase of up to $200 million of Class A common stock. TKO Group Holdings Inc. (NYSE:TKO) remains focused on disciplined capital deployment and high-quality execution to provide value to its shareholders through these structured financial maneuvers.

TKO Group Holdings Inc. (NYSE:TKO) is a sports company that operates through three segments: UFC, WWE, and IMG. The company also merchandises video games, apparel, equipment, and digital goods.

7. Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is one of the best future stocks to buy for the next 5 years. On March 30, Alnylam Pharmaceuticals presented new clinical and real-world data at the American College of Cardiology’s Annual Scientific Session/ACC.26 regarding its cardiovascular portfolio. The findings highlight the benefits of vutrisiran, which is an RNAi therapeutic that silences transthyretin/TTR at the source, for patients with transthyretin-mediated amyloidosis with cardiomyopathy/ATTR-CM.

Data from the HELIOS-B analysis showed that vutrisiran improved health-related quality of life and functional outcomes, with treatment effects in older patients appearing comparable to those observed in individuals more than a decade younger. The presentation detailed vutrisiran’s efficacy across the disease spectrum, including those with advanced illness and diastolic dysfunction.

Regarding the hypertension pipeline, Alnylam shared pooled Phase 2 safety data for zilebesiran, an investigational RNAi therapeutic designed to provide continuous blood pressure control through biannual dosing. The results support the ongoing evaluation of zilebesiran in the ZENITH Phase 3 Cardiovascular Outcomes Trial, which was initiated in late 2025 to address cardiovascular risk reduction.

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is a biotechnology company that develops therapeutics based on ribonucleic acid interference. The company currently has a range of products in Phase 3, Phase 2, and Phase 1 trials.

6. Takeda Pharmaceutical Company Limited (NYSE:TAK)

Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the best future stocks to buy for the next 5 years. On March 2, Takeda and Protagonist Therapeutics announced that the US FDA accepted the NDA and granted Priority Review for rusfertide. An investigational, first-in-class hepcidin mimetic peptide, rusfertide is intended for the treatment of adults with polycythemia vera/PV. The FDA established a Prescription Drug User Fee Act target action date within Q3 2026. This milestone follows previous Breakthrough Therapy, Orphan Drug, and Fast Track designations granted to the therapeutic.

The regulatory submission is primarily supported by results from the Phase 3 VERIFY study and long-term data from the Phase 2 REVIVE and THRIVE studies. In the VERIFY trial, rusfertide combined with standard of care more than doubled clinical response rates compared to standard care alone. Patients experienced improvements in hematocrit control, a reduction in the need for phlebotomy, and improved patient-reported outcomes regarding fatigue and symptom burden.

Takeda Pharmaceutical Company Limited (NYSE:TAK) and Protagonist entered a worldwide license and collaboration agreement for rusfertide in January 2024. Under this partnership, Protagonist led the development through Phase 3, while Takeda is responsible for the US regulatory strategy and future global filings.

Takeda Pharmaceutical Company Limited (NYSE:TAK) is a healthcare company that develops pharmaceutical products for gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience.

5. Intel Corporation (NASDAQ:INTC)

Intel Corporation (NASDAQ:INTC) is one of the best future stocks to buy for the next 5 years. On April 1, Intel Corporation and Apollo announced a definitive agreement for Intel to repurchase a 49% equity interest in their JV related to Fab 34 in Ireland for $14.2 billion. This transaction marks the conclusion of a partnership established in 2024, when Apollo-managed funds invested $11.2 billion to provide Intel with the financial flexibility needed to accelerate its advanced manufacturing roadmap.

The buyback is driven by Intel’s strengthened balance siscipline,heet, improved financial d and a strategy centered on the essential role of CPUs in the AI era. The repurchase will be funded through a combination of cash on hand and ~$6.5 billion in new debt issuance. Intel expects the transaction to be accretive to its ongoing EPS and to strengthen its overall credit profile starting in 2027. Despite the new debt, the company maintains its commitment to retiring existing debt maturities as they come due in 2026 and 2027, reflecting a realignment of its capital structure with long-term operational priorities.

Fab 34 remains a critical component of Intel’s global manufacturing footprint, serving as a high-volume facility for Intel 4 and Intel 3 process technologies used in Core Ultra and Xeon 6 processors. Both David Zinsner, Intel Corporation (NASDAQ:INTC) CFO, and Jamshid Ehsani, Apollo Partner, emphasized the success of the initial capital infusion in advancing next-gen chip production in Europe. Intel plans to continue investments in its Ireland campus to expand capacity and support the increasing demand for AI-enabled systems.

Intel Corporation (NASDAQ:INTC) is a semiconductor company specializing in computing & related end products and services through its CCG, DCAI, and Intel Foundry segments.

4. Palantir Technologies Inc. (NASDAQ:PLTR)

Palantir Technologies Inc. (NASDAQ:PLTR) is one of the best future stocks to buy for the next 5 years. On March 30, Palantir Technologies announced a five-year renewal and expansion of its long-standing partnership with Stellantis, extending a collaboration that originally began in 2016. This new agreement is designed to support the automotive giant in the further industrialization of its data and AI capabilities.

The partnership focuses on transitioning Stellantis into an AI-powered industrial enterprise by embedding secure and governed data practices across its global operations. Under the terms of the expanded deal, Stellantis will increase its use of the Palantir Technologies Inc. (NASDAQ:PLTR) Foundry platform and begin deploying the Palantir Artificial Intelligence Platform/AIP in specific regions and business functions.

Foundry provides a unified environment for managing complex industrial data, while AIP allows teams to integrate GenAI into existing workflows. Together, these tools are intended to consolidate fragmented datasets, improve transparency, and accelerate decision-making processes within the company’s complex manufacturing and operational structures. The integration of AIP uses Stellantis’ existing data ontology to connect AI capabilities directly to internal business rules and decision-making logic.

Palantir Technologies Inc. (NASDAQ:PLTR) is a software-infrastructure company that develops software platforms to assist in counterterrorism investigations and operations.

3. Eli Lilly and Company (NYSE:LLY)

Eli Lilly and Company (NYSE:LLY) is one of the best future stocks to buy for the next 5 years. On April 1, Eli Lilly announced the FDA approval of Foundayo (orforglipron), the first once-daily GLP-1 receptor agonist pill for chronic weight management that can be taken without food or water restrictions. Indicated for adults with obesity or overweight with weight-related comorbidities, the medication is designed to be used alongside a reduced-calorie diet and increased physical activity.

Foundayo will be available starting April 6, through LillyDirect and retail pharmacies, with a pricing structure starting at $25 per month for those with commercial insurance and $149 for self-pay patients. The approval is supported by the ATTAIN-1 clinical trial, where participants on the highest dose lost an average of 27.3 pounds (12.4%) over 72 weeks, compared to just 2.2 pounds for the placebo group.

Beyond weight reduction, the trial showed improvements in cardiovascular risk markers, such as systolic blood pressure and cholesterol levels. Unlike previous oral GLP-1 treatments, Foundayo’s small-molecule formulation allows for flexible dosing at any time of day, addressing a significant practical barrier for many patients seeking non-injectable obesity care. Eli Lilly and Company (NYSE:LLY) has already submitted orforglipron for regulatory approval in over 40 countries, aiming to expand global access to this oral treatment for both weight management and type 2 diabetes.

Eli Lilly and Company (NYSE:LLY) is a healthcare company that develops human pharmaceutical products, including cardiometabolic health, oncology, and immunology products.

2. Broadcom Inc. (NASDAQ:AVGO)

Broadcom Inc. (NASDAQ:AVGO) is one of the best future stocks to buy for the next 5 years. On March 24, Broadcom and Carahsoft Technology Corp. announced a five-year, $970 million blanket purchase agreement/BPA with the Defense Information Systems Agency/DISA. This agreement consolidates existing software contracts to provide uniform pricing and cost transparency across multiple Department of War/DoW agencies, including the US Air Force, US Space Force, and various Combatant Commands.

Held by Carahsoft, the contract streamlines the acquisition of the VMware Cloud Foundation/VCF platform and other critical infrastructure solutions. The partnership enhances mission capabilities through the deployment of a unified private cloud platform. VCF integrates the scalability of public clouds with the security and architectural control of on-premises environments, supporting traditional, cloud-native, and AI applications.

According to Broadcom Inc. (NASDAQ:AVGO), upgrading to this modern infrastructure can significantly reduce the total cost of ownership compared to traditional systems by lowering hardware and facility expenses while enabling agencies to operationalize Zero Trust security and accelerate AI model deployment. In addition to cloud infrastructure, the agreement includes specialized tools such as VMware vDefend for lateral security and Broadcom’s Clarity for strategic portfolio management.

Broadcom Inc. (NASDAQ:AVGO) is a technology company that specializes in semiconductor devices (through the Semiconductor Solutions segment) and infrastructure software solutions (through the Infrastructure Software segment).

1. Taiwan Semiconductor Manufacturing Co. Ltd. (NYSE:TSM)

Taiwan Semiconductor Manufacturing Co. Ltd. (NYSE:TSM) is one of the best future stocks to buy for the next 5 years. On April 1, Reuters reported that Taiwan Semiconductor Manufacturing Co. Ltd., or simply TSMC, is set to launch 3-nanometre wafer production at its second factory in Japan in 2028. According to a Taiwanese government filing, the facility will have a monthly capacity of 15,000 12-inch wafers using this advanced process technology.

This follows a February meeting between TSMC CEO CC Wei and Japan’s Prime Minister Sanae Takaichi, where the shift toward more sophisticated semiconductor manufacturing was first indicated. This strategy marks an advancement from TSMC’s earlier plans for its Japanese operations, which initially focused on less-advanced nodes. While the first fabrication plant began volume production in late 2024, the total investment for the first two facilities is expected to exceed $20 billion.

Reports suggest the second factory alone could require ~$17 billion in investment, though Taiwan Semiconductor Manufacturing Co. Ltd. (NYSE:TSM) has not officially confirmed that specific figure. The venture is managed through Japan Advanced Semiconductor Manufacturing/JASM, a unit established in 2021 with support from Sony Semiconductor Solutions Corporation. Together, these facilities are projected to reach a combined monthly capacity of 100,000 12-inch wafers, spanning a range of technologies from 40-nanometre down to the new 3-nanometre standard.

Taiwan Semiconductor Manufacturing Co. Ltd. (NYSE:TSM) is a technology company that develops ICs and other semiconductor devices. Its products are used in HPC, smartphones, IoT, automotive, and consumer electronics.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. None. Follow Insider Monkey on Google News.